Abstract
Cutaneous melanoma (CM) is the fourth tumor in frequency, and that whose incidence increases faster. In half of the cases, CM arises from pre-existing nevi. CM is a highly heterogeneous tumor, whose degree of differentiation varies among different hosts, and such heterogeneity is probably based on the accumulation of mutations that determine transitions from normal melanocytic stem cells → mutated benign melanocytic stem cells → malignant melanocytic stem cells → clonogenic melanocytic cells. These populations may express different antigens and would therefore trigger the proliferation of different T and B cell clones. Early diagnosis is the clue for the cure of CM; when visceral metastatic disease is established, the prognosis is somber. This is especially so since CM is quite resistant to chemotherapy, and some of the reasons for such resistance will be discussed here. However, CM has proved to be sensitive to immunological effectors, although the mechanism of such sensitivity is still being investigated. These effectors range from therapeutic vaccines, in vitro expanded cytotoxic lymphocytes, cytokines, and monoclonal antibodies. Finally, we will discuss new therapeutic approaches that include the combination of immune modulators and vaccines which are being assayed in light of recent tumor immunology research.
Keywords: Melanoma development, chemotherapy and resistance, immunotherapy, cancer vaccines
Current Cancer Therapy Reviews
Title: Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Volume: 6 Issue: 3
Author(s): Mariana Aris, Maria M. Barrio and Jose Mordoh
Affiliation:
Keywords: Melanoma development, chemotherapy and resistance, immunotherapy, cancer vaccines
Abstract: Cutaneous melanoma (CM) is the fourth tumor in frequency, and that whose incidence increases faster. In half of the cases, CM arises from pre-existing nevi. CM is a highly heterogeneous tumor, whose degree of differentiation varies among different hosts, and such heterogeneity is probably based on the accumulation of mutations that determine transitions from normal melanocytic stem cells → mutated benign melanocytic stem cells → malignant melanocytic stem cells → clonogenic melanocytic cells. These populations may express different antigens and would therefore trigger the proliferation of different T and B cell clones. Early diagnosis is the clue for the cure of CM; when visceral metastatic disease is established, the prognosis is somber. This is especially so since CM is quite resistant to chemotherapy, and some of the reasons for such resistance will be discussed here. However, CM has proved to be sensitive to immunological effectors, although the mechanism of such sensitivity is still being investigated. These effectors range from therapeutic vaccines, in vitro expanded cytotoxic lymphocytes, cytokines, and monoclonal antibodies. Finally, we will discuss new therapeutic approaches that include the combination of immune modulators and vaccines which are being assayed in light of recent tumor immunology research.
Export Options
About this article
Cite this article as:
Aris Mariana, M. Barrio Maria and Mordoh Jose, Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698232
DOI https://dx.doi.org/10.2174/157339410791698232 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Optimized Approach for Breast Cancer Classification for Histopathological Images Based on Hybrid Feature Set
Current Medical Imaging Nuclear Targeting and Retention of Anthracycline Antitumor Drugs in Sensitive and Resistant Tumor Cells
Current Medicinal Chemistry Piperidin-4-one: The Potential Pharmacophore
Mini-Reviews in Medicinal Chemistry Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Genetic Profile of SNP(s) and Ovulation Induction
Current Pharmaceutical Biotechnology Advances of Metal Enhanced Fluorescence Applications for the Biomedical Field
Current Proteomics Structure-Function Relationships in the Interaction Between the Urokinase- Type Plasminogen Activator and Its Receptor
Current Pharmaceutical Design Organocatalysis in the Synthesis of Natural Products: Recent Developments in Aldol and Mannich Reactions, and 1,4-Conjugated Additions
Current Organocatalysis The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Current Medicinal Chemistry Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry Inhibitory Effect of Sesamolin on Melanogenesis in B16F10 Cells Determined by In Vitro and Molecular Docking Analyses
Current Pharmaceutical Biotechnology Melanoma: The Radiotherapeutic Point of View; Review of the Current Literature
Reviews on Recent Clinical Trials Novel Dual Inhibitors of Nuclear Factor-Kappa B (NF-κ B) and Cyclooxygenase- 2 (COX-2): Synthesis, In Vitro Anticancer Activity and Stability Studies of Lantadene–Non Steroidal Anti-inflammatory Drug (NSAID) Conjugates
Current Topics in Medicinal Chemistry Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets The Role of a Disturbed Arginine/NO Metabolism in the Onset of Cancer Cachexia: A Working Hypothesis
Current Medicinal Chemistry Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes
Current Topics in Medicinal Chemistry